Krystal Biotech, Inc. (KRYS) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$288.89
Price Target
$332.75
Target Range
$310.00 — $371.00
Analyst Rating
Buy
Forward P/E38.3x
Trailing P/E42.2x
Forward PEG—
Implied Growth+2.3%
Median Target$325.00
Analyst Spread18.3%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$310
+7.3%
Consensus
$333
+15.2%
Bull Case
$371
+28.4%
KRYS Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Krystal Biotech, Inc. (KRYS) has a Wall Street consensus price target of $332.75, based on estimates from 17 covering analysts. With the stock currently trading at $288.89, this represents a potential upside of +15.2%. The company has a market capitalization of $8.52B.
Analyst price targets range from a low of $310.00 to a high of $371.00, representing a 18% spread in expectations. The median target of $325.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 17 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, KRYS trades at a trailing P/E of 42.2x and forward P/E of 38.3x. Analysts expect EPS to grow +2.3% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+434.4%
Avg Forward P/E32.3x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RCKTRocket Pharmaceuticals, Inc. | $418M | $3.86 | $5.00 | +29.5% | Buy | — | 19 |
 RAREUltragenyx Pharmaceutical Inc. | $2.5B | $25.93 | $51.50 | +98.6% | Buy | — | 33 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 ACADACADIA Pharmaceuticals Inc. | $3.7B | $21.48 | $34.78 | +61.9% | Buy | 48.5x | 37 |
 PTCTPTC Therapeutics, Inc. | $5.5B | $66.61 | $89.67 | +34.6% | Buy | — | 26 |
 SRPTSarepta Therapeutics, Inc. | $2.4B | $23.03 | $24.63 | +6.9% | Buy | 7.7x | 54 |
 CRSPCRISPR Therapeutics AG | $5.3B | $55.08 | $63.00 | +14.4% | Buy | — | 38 |
 EDITEditas Medicine, Inc. | $311M | $3.17 | $6.00 | +89.0% | Buy | — | 25 |
 BEAMBeam Therapeutics Inc. | $3.3B | $32.33 | $40.83 | +26.3% | Buy | — | 27 |
 SGMOSangamo Therapeutics, Inc. | $38M | $0.18 | $7.25 | +3982.2% | Hold | — | 14 |
Upside Potential Comparison
SGMORAREEDITACADPTCTRCKTBEAMCRSPSee KRYS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KRYS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KRYS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKRYS — Frequently Asked Questions
Quick answers to the most common questions about buying KRYS stock.
What is the KRYS stock price target for 2026?
Krystal Biotech, Inc. (KRYS) has a consensus 12-month price target of $332.75, implying 15.2% upside from $288.895. The 17 analysts covering KRYS see moderate appreciation potential.
Is KRYS a buy, sell, or hold?
KRYS has a consensus rating of "Buy" based on 17 Wall Street analysts. The rating breakdown is predominantly bullish, with 17 Buy/Strong Buy ratings. The consensus 12-month price target of $332.75 implies 15.2% upside from current levels.
Is KRYS stock overvalued or undervalued?
At a forward P/E of 38.2926x, KRYS trades at a premium valuation. The consensus price target of $332.75 (15.2% upside) suggests analysts still see growth justifying the multiple.
How high can KRYS stock go?
The most bullish Wall Street analyst has a price target of $371 for KRYS, while the most conservative target is $310. The consensus of $332.75 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover KRYS stock?
KRYS is well covered by analysts, with 17 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 17 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the KRYS stock forecast?
The 12-month KRYS stock forecast based on 17 Wall Street analysts shows a consensus price target of $332.75, with estimates ranging from $310 (bear case) to $371 (bull case). The median consensus rating is "Buy".
What is KRYS's forward P/E ratio?
KRYS trades at a forward P/E ratio of 38.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 42.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy KRYS stock?
Wall Street analysts are optimistic on KRYS, with a "Buy" consensus rating and $332.75 price target (15.2% upside). 17 of 17 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do KRYS price targets vary so much?
KRYS analyst price targets range from $310 to $371, a 18% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $332.75 consensus represents the middle ground.